can semaglutide make you go blind Ozempic Vision Loss Lawsuit [2026 Update] Popular weight loss and diabetes

As the use of GLP-1 receptor agonists continues to expand for the treatment of type 2 diabetes and obesity, questions have emerged about their potential gastrointestinal side effectsparticularly gastroesophageal reflux disease (GERD)

Includes sample charts, dosing comparisons, safety considerations, and key guidance for individuals seeking a gentler titration approach under medical supervision.

Amongst, overweight and obese patients defined by BMI in 2024 (58.9% [95% CIs 53.3-64.2%] female [182/309], median [IQR] age 56.6 [46.2-66.1]) GLP 1RA use has increased from 3.2% (10/309 [95% CIs 1.8-5.9%]) to 13.6% (42/309 [95% CIs 10.2-17.9%] [p=7.1x10-6])

99% purity verified by HPLC with batch-level COAs available

GLP-1R-immunolabeling was also robust in dendrites and axons, especially in laminae IIIII in the dorsal horn